Nanjing King-Friend Biochemical Pharmaceutical released its semi-annual report for 2024, with a revenue of 2.143 billion yuan, a decrease of 6.99% comparing to the same period last year; the net income attributable to shareholders of the listed company is 0.405 billion yuan, a decrease of 35.15%.
健友股份：上半年净利润4.05亿元 同比下降35.15%
Nanjing King-Friend Biochemical Pharmaceutical: Net income for the first half of the year is 0.405 billion yuan, a decrease of 35.15% compared to the same period last year.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.